Lonza Group Profile
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide.
The company serves Healthcare Continuum and selected other targeted markets through a range of products and services in its Pharma & Biotech; and Specialty Ingredients segments.
The company provides full-service offerings to its customers in the pharma, healthcare and industrial markets – from the molecule to the patient, from nutritional ingredients to value-added consumer solutions and from microbial control ingredients to safe surroundings. The company offers ranges from custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Pharma & Biotech
The Pharma & Biotech market consists of clinical development services and manufacturing in biologics and small-molecule businesses; commercial manufacturing in biologics and small-molecule Businesses; and consumables and research tools.
The company serves its customers throughout the product lifecycle – for all clinical manufacturing needs and through the transition of their products to commercial manufacturing.
The company is a commercial contract manufacturing provider for biopharmaceuticals. Its offerings include the manufacture of commercial drug substance of monoclonal antibodies (mAbs) and recombinant proteins from mammalian cell culture and microbial fermentation. The company’s manufacturing product portfolio includes products that represent essential active pharmaceutical ingredients for life-saving medicines, including cancer treatments and orphan drugs for rare diseases where no alternative treatment exists. The company’s knowhow and platform technologies enable its customers to define their own tailored solution from a range of services. Its GS Xceed Gene Expression System for mammalian expression and its XS Technologies for microbial expression include processes for compliant commercial manufacture.
The company’s Clinical Development and Manufacturing business focuses on the early phase of drug development, from late discovery through clinical trial supply. In 2018, the company offered a broad portfolio of drug substance and drug product development services and clinical supply manufacturing across the mammalian and microbial modalities. Its technologies include its Epibase in silico and in vitro, cellular immunogenicity screening, and its antibody humanization and deimmunization services.
The company’s Sentinel APART Platform serves as a tool for antibody aggregation prediction and re-engineering, and its manufacturability assessment service is used to help predict and mitigate manufacturing risk.
In September 2018, the company expanded its Ibex Solutions facility in Visp, with two new, packages – Ibex Design and Ibex Develop. Ibex Design covers the early stages of creating a new biologic, from gene through to clinical phase I. Ibex Develop helps companies transition from clinical phase II to commercialization.
The company’s Bioscience Solutions offerings include cell-culture, transfection and endotoxin testing tools for the life-science industry. It serves customers across the world in academic and government institutions, as well as in major biotech and pharmaceutical organizations. Its Bioscience Solutions team provides products and customer services in life-science research with its Biowhittaker Cell Culture Media, Clonetics and Poietics primary cells and media, Nucleofector Transfection technology and CellBio Services custom solutions. For the drug-discovery and translational research markets, the company offers products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer and other disease-research areas. Bioscience Solutions’ therapeutic cell-culture media business serves customers in the pharmaceutical and biotech industry. Lonza Testing Solutions offers endotoxin-detection assays that are applied in pharmaceutical product-release testing, medical-device testing and dialysis clinics to help ensure the safety of injectable drugs, implantable medical devices and dialysis equipment.
Specialty Ingredients
In 2018, the Specialty Ingredients segment operated in a Consumer Health division; a Consumer & Resources Protection division; and a Water Care business unit.
The Consumer Health division addressed the consumer goods markets in nutritional ingredients for supplements and functional food, hygiene and personal care. The Consumer & Resources Protection division addressed a range of industrial markets, as well as the global agricultural markets. The Water Care business unit offered a range of products and solutions for residential and industrial water treatment globally.
Consumer Health
The Consumer Health division within the company’s Specialty Ingredients segment is uniquely positioned to address consumer needs in human and pet nutrition, personal care, and home and professional hygiene through its portfolio of science-backed ingredients, formulation expertise and dosage form delivery capabilities.
The company’s health and nutrition businesses offer customers fully integrated solutions from concept through product commercialization. It supplies branded health ingredients that address the key market segments in the nutritional supplement category, along with regulatory and commercial support.
The company’s personal care business serves the global beauty and markets as an established supplier of functional ingredients, such as specialty plant-based emulsifiers and aesthetic modifiers, and traditional and next-generation preservation and protection systems. Lonza nutritional supplements offerings introduced in 2018 included Vcaps Plus capsules; Vcaps Plus Spirulina Capsules; and Vcaps Plus Purple Carrot Capsules.
With the launch of two Bioactive Functional ingredients, ScreenLight Block and XPressEV, the Personal Care business demonstrated the company’s commitment to investing in solutions that meet its customers’ needs. ScreenLight Block provides a defensive shield against the visible skin-aging effects of blue light and environmental stressors, such as UV light and pollution. The company’s coatings and composites businesses serve global markets with a range of specialty solutions for the protection, enhanced performance and modification of the end-use characteristics of various materials, including carbon fibers, fabrics, leather, metals, plastics, stone and wood.
The company’s specialty biocide and non-biocide products are used to produce coatings that are applied superficially or by penetrating processes. It also delivers specialty solutions for in-process or end-of-process application in the manufacture of various composite materials (e.g. wood-plastic composites, laminated veneer, wood-based products, etc.). Its composite thermoset resin systems are used in modern consumer electronics to help enhance performance, as well as in the production of structural and interior elements for passenger aircraft.
The company’s agricultural businesses provide products and contract manufacturing services designed to improve crop yields and food quality. It supplies products and services to industrial customers, as well as finished products for end use by agricultural enterprises and farmers. The company’s offerings to the agricultural markets are derived from unrelenting focus on customers’ needs and requirements and are based on its expertise in chemical and biological technology. The company’s custom manufacturing supports customers in the production of modern herbicides, insecticides and fungicides, including biologically derived products, such as biopesticides, biostimulants and other microbial active ingredients and intermediates. Its services also include full life-cycle management for customers’ products. Its vitamin B3 compounds (niacin and niacinamide) and its Carniking and LaraFeed products. For the beneficial impact of Carniking on the performance and recovery in active dogs, Lonza has been granted a U.S. patent.
In its agricultural business, the company offers various solutions to help farmers protect their crops. Its active ingredient META metaldehyde and its formulated products, marketed under the Axcela brand, are all sold globally. Slugs and snails could pose significant problems for both the professional grower of agricultural crops and gardeners. In 2018, the company successfully expanded its product offering through geographical and portfolio expansion in New Zealand, South Korea, Taiwan, Turkey, Germany and France. The company offers HTH Text Strips; HTH and Spa Selections; Pulsar Infinity and CCH Endurance Feeder Systems; and Pond-Klear.
Strategy
The company’s strategy is to be the leading integrated, value-adding solutions provider for the Healthcare Continuum. Its strategy is to focus on innovative, value-enhancing products and services for its customers that help to deliver the medicines to bring preventive healthcare solutions to consumers and to contribute to a safe living environment.
History
Lonza Group Ltd was founded in 1897.
